Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Guided Therapeutics (GTHP) over the last 10 years, with Q3 2025 value amounting to -$277000.0.

  • Guided Therapeutics' Cash from Operations rose 4143.76% to -$277000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 124.67%. This contributed to the annual value of -$1.1 million for FY2024, which is 3591.07% up from last year.
  • Guided Therapeutics' Cash from Operations amounted to -$277000.0 in Q3 2025, which was up 4143.76% from -$169000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Cash from Operations high stood at $159000.0 for Q4 2021, and its period low was -$739000.0 during Q3 2021.
  • Over the past 5 years, Guided Therapeutics' median Cash from Operations value was -$336000.0 (recorded in 2023), while the average stood at -$353315.8.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 14803.63% in 2021, then plummeted by 31320.75% in 2022.
  • Guided Therapeutics' Cash from Operations (Quarter) stood at $159000.0 in 2021, then crashed by 313.21% to -$339000.0 in 2022, then rose by 0.88% to -$336000.0 in 2023, then grew by 1.19% to -$332000.0 in 2024, then grew by 16.57% to -$277000.0 in 2025.
  • Its last three reported values are -$277000.0 in Q3 2025, -$169000.0 for Q2 2025, and -$331000.0 during Q1 2025.